CGC vs. USNA, CRON, MNMD, BTMD, ACB, CDXC, IMTX, AORT, TYRA, and BCYC
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include USANA Health Sciences (USNA), Cronos Group (CRON), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Immatics (IMTX), Artivion (AORT), Tyra Biosciences (TYRA), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
USANA Health Sciences (NYSE:USNA) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
USANA Health Sciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
USANA Health Sciences has a net margin of 6.88% compared to USANA Health Sciences' net margin of -326.75%. Canopy Growth's return on equity of 12.80% beat USANA Health Sciences' return on equity.
54.3% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 0.3% of USANA Health Sciences shares are owned by insiders. Comparatively, 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, USANA Health Sciences had 10 more articles in the media than Canopy Growth. MarketBeat recorded 17 mentions for USANA Health Sciences and 7 mentions for Canopy Growth. USANA Health Sciences' average media sentiment score of 0.89 beat Canopy Growth's score of 0.64 indicating that Canopy Growth is being referred to more favorably in the news media.
USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences currently has a consensus target price of $46.00, suggesting a potential downside of 3.26%. Canopy Growth has a consensus target price of $4.87, suggesting a potential downside of 49.83%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe USANA Health Sciences is more favorable than Canopy Growth.
USANA Health Sciences received 375 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 60.68% of users gave USANA Health Sciences an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
Summary
USANA Health Sciences beats Canopy Growth on 14 of the 18 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
